Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01752712 · ClinicalTrials.gov registry record · NA

Oxytocin and CBSST for People With Schizophrenia

A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by University of Maryland, Baltimore.

Completed
Registry status
NA
Development phase
83
Enrollment target
2
Study locations

NCT01752712: Completed NA study of Schizophrenia and Schizoaffective Disorder, sponsored by University of Maryland, Baltimore.

NCT01752712 is a NA study of Schizophrenia and Schizoaffective Disorder that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 83 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01752712, a NA study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
NA
Development phase
83 participants
Enrollment target
2
Study locations

Study Summary

A significant proportion of people with schizophrenia are characterized by impaired ability to socially engage with others, which may reflect social aversion secondary to defeatist beliefs; decreased motivation for social interactions; and/or impairment in the normal reinforcement value of social interactions. These impairments in social function have been shown to be associated with social skill deficits; and decreased ability to identify and remember emotional facial expressions and empathize with the emotional status of others. Unfortunately, pharmacological interventions have limited benefits for impaired social function, whereas psychosocial interventions provide only partial benefit for this critical aspect of the illness. The development of an effective intervention for functional outcomes remains a central therapeutic challenge. Cognitive Behavioral Social Skills Training (CBSST) uses corrective feedback and reinforcement provided by successful interactions to challenge and reduce defeatist performance beliefs that contribute to low drive and interfere with social functioning. CBSST has been shown to have modest effects on social function in people with schizophrenia. Oxytocin plays a critical role in the regulation of normal social affiliative behavior; it is hypothesized to enhance social affiliation through the reduction of anxiety or social risk aversion; the enhancement of motivation for prosocial approach behavior; and/or increased modulation of the salience and processing of social cues. People with schizophrenia have decreased oxytocin levels, which are associated with an impaired ability to identify facial emotions and decreased prosocial behaviors. The study will be comprised of three phases: 1) 2-week Evaluation Phase; 2) 24-week Double-blind Treatment Phase; and 3) 3-month Follow-up Phase.

Primary Outcome

Determine if CBSST + oxytocin compared to CBSST + placebo is associated with improved social function. There are 7 individual sections, with each section asking about different aspects of social functioning. Scores for Section 1: "Social Engagement Withdrawal" range from 0-15; Section 2: "Interpersonal Communication/Relationships" ranges from 0-30; Section 3: "Prosocial Activities" range is 0-66; Section 4: "Recreation" ranges from 0-48; Section 5: "Independence (Performance)" ranges from 0-39;

Interventions

  • DRUG CBSST + Oxytocin
  • DRUG CBSST + Placebo

Study Locations (2)

California

  • University of California, San Diego - San Diego

Maryland

  • Maryland Psychiatric Research Center - Baltimore

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2014-01
Est. Completion 2016-08
Phase NA
University of Maryland, Baltimore

560 total trials

What the finished NCT01752712 record still lists

NCT01752712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (62% lower).

The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which CBSST + Oxytocin is the first listed.

NCT01752712 reports a single indexed study location in California, Maryland.

Frequently Asked Questions

What is clinical trial NCT01752712 about?

NCT01752712 is a clinical study titled "Oxytocin and CBSST for People With Schizophrenia". A significant proportion of people with schizophrenia are characterized by impaired ability to socially engage with others, which may reflect social aversion secondary to defeatist beliefs; decreased motivation for social interactions; and/or impairment in the normal reinforcement value of social in...

What is the current status of trial NCT01752712?

This trial is currently completed. It is a NA study. The enrollment target is 83 participants. The study started on 2014-01. Estimated completion is 2016-08.

What conditions does trial NCT01752712 study?

This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.

What interventions are being tested in trial NCT01752712?

The interventions under investigation include: CBSST + Oxytocin (DRUG), CBSST + Placebo (DRUG).

Who is sponsoring clinical trial NCT01752712?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01752712 being conducted?

This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01752712's enrollment target sits among peer trials

83 158th of 315 higher than 158 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02974647 · 83 participants · Phase 2

    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

  • NCT03919292 · 83 participants · Phase 1

    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

  • NCT04626674 · 83 participants · Phase 1

    A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  • NCT05277168 · 83 participants · Phase 1

    A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01752712, the US trial registry maintained by the National Library of Medicine. NCT01752712 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.